Oncolytic adenovirus encoding a therapeutic protein or active fragment
US10548929B2 · kind B2 · utility
3Cited by
2References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 3, 2017 |
| Grant date | Feb 4, 2020 |
| Priority date | — |
| Expiry date | Jul 14, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/10371
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides a oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a membrane anchored anti-CD3 antibody or a binding fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.